- $411.65m
- $327.77m
- CA$284.60m
Corrected: BRIEF-Canopy Growth Corp Q4 Revenue CAD 71.24 Million Vs. IBES Estimate CAD 74.4 Million
Brief: Canopy Growth Relaunches Tweed Brand In Germany With New Mtl Cannabis Strain Lineup, Marking First International Release Following Acquisition
Brief: Canopy Growth And Spectrum Therapeutics Expand Medical Portfolio With New 30 And 90-Pack Softgels And Enhanced Dosing Options
Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis shares retreat after initial rally on narrow scope of US rescheduling (updated)
Explainer: How US marijuana reclassification could help cannabis companies
Pot firms rally after US reclassifies marijuana as less dangerous drug
Explainer: How US marijuana reclassification could help cannabis companies
DOJ reclassifies certain marijuana products as a less-dangerous drug (updated)
DOJ reclassifies FDA-approved, state-licensed marijuana as a less-dangerous drug
Explainer: How US marijuana reclassification could help cannabis companies
Pot stocks rise as report says US set to reclassify marijuana
US set to reclassify marijuana as early as Wednesday, Axios reports (updated)
Brief: Canopy Growth Announces Storz & Bickel Executive Transition
Brief: Canopy Growth Completes Acquisition Of Mtl Cannabis Creating Canada’S Leading Medical Cannabis Business By Revenue
Canopy Growth Q3 revenue beats estimates driven by insured patients, larger orders
Brief: Canopy Growth Files For Offering Of Up To 52.3 Million Shares By The Selling Securityholders
Explainer: How US marijuana reclassification could help cannabis companies
Explainer: How US marijuana reclassification could help cannabis companies